SG investors.io
Market
FTSE ST Indices & STI Constituents
SGX Market
Share Price Performance
SGX Top Volume Counters
SGX Top Trading Value Counters
SGX Top Gainers (%)
SGX Top Gainers ($)
SGX Top Losers (%)
SGX Top Losers ($)
Price & Volume Breakout - 3 Months High
Price & Volume Breakout - 3 Months Low
Price Breakout - 52 Weeks High
Price Breakout - 52 Weeks Low
Volume Breakout - Surging Volume
SGX Top Short Sell By Volume
SGX Top Short Sell By Value
Market Updates By SGX My Gateway
SGX Market Fund Flow Overview
SGX Cumulative Fund Flow By Sector
SGX Weekly Fund Flow By Sector
SGX Top Active Stocks
SGX Stocks
S-REITs
Analysts Say
Analysts Say
Stocks & REITs Analyst Reports
Market Strategy & Research Report
Sector / Industry Research Reports
Latest Price Targets & Stock Ratings
Price Targets with Substantial Upside / Downside Potential
Average Target Price & Fair Value Recommendations
STI Constituents Price Targets & Stock Ratings
S-REITs Price Targets & Ratings
Model Portfolios
Bloggers Say
News Feed
Latest Business News
Latest Corporate Announcements
Latest Share Buy Back Transactions
Upcoming Dividends / Entitlements
Earnings Calendar
Singapore Stock Brokerages
Analyst Recommendation Framework
SGD Currency Exchange Rates
FTSE ST Index
About Us
SGinvestors.io
>
Analysts Say
> Research Report
iX Biopharma - CGS-CIMB Research 2021-12-14: Wafermine Out-Licensed For ~US$248mil
iX Biopharma - Wafermine Out-Licensed For ~US$248mil
SGinvestors.io
Published:
2021-12-15 10:07 PM
IX BIOPHARMA LTD.
(
SGX:42C
)
IX BIOPHARMA LTD. (SGX:42C)
IX BIOPHARMA LTD. (SGX:42C)
IX BIOPHARMA LTD. (SGX:42C)